Get the Stockscreener App
1.84
1.10%
0.02
After Hours:
1.92
0.08
+4.35%
Allogene Therapeutics Inc stock is traded at $1.84, with a volume of 3.20M.
It is up +1.10% in the last 24 hours and down -1.60% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.82
Open:
$1.82
24h Volume:
3.20M
Relative Volume:
1.23
Market Cap:
$385.80M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.8679
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-4.17%
1M Performance:
-1.60%
6M Performance:
-34.98%
1Y Performance:
-40.45%
1-Day Range:
$1.78
$1.905
1-Week Range:
$1.78
$2.10
52-Week Range:
$1.78
$5.775
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.84 | 385.80M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Barclays PLC Buys 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
JPMorgan Chase & Co. Sells 37,348 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
What is Zacks Research's Forecast for ALLO Q2 Earnings? - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $9.73 Consensus Price Target from Brokerages - MarketBeat
Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World
Geode Capital Management LLC Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLC - Defense World
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
State Street Corp Has $19.64 Million Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - MSN
Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada
Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com
Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector Decline - GuruFocus.com
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire
Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com
Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha
Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decrease in Short Interest - MarketBeat
Allogene Therapeutics Loses 23% Year To Date: How To Play The Stock? - Barchart
Vestal Point Capital LP Trims Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells - BioWorld Online
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth? - Simply Wall St
Allogene stock touches 52-week low at $2 amid market challenges - Investing.com India
Allogene's Q3 Loss Narrower Than Expected, Sales Nil - MSN
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):